The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
In a nationwide cohort of patients with T2D and AF, SGLT2 inhibitor was associated with a lower risk of mortality, which may suggest that SGLT2 inhibitors may be considered as the first-line antidiabetic medication in patients with T2D and AF.
Authors
- Young Ju Suh (ORCID: https://orcid.org/0000-0002-6816-8067)
- Sojeong Park (ORCID: https://orcid.org/0000-0001-6019-6912)
- Yongin Cho (ORCID: https://orcid.org/0000-0002-4645-816X)
- Dae-Young Kim (ORCID: https://orcid.org/0000-0002-0649-9100)
- Sung‐Hee Shin (ORCID: https://orcid.org/0000-0002-8306-9622)
- So Hun Kim
- Min-Ae Park
- Ji-Hun Jang
Institutions
- Inha University (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1371/journal.pone.0314454
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Inha University